Objectives: To determine whether sacral neuromodulation (SNM) for urinary symptoms or fecal incontinence gives improvement of female sexual function and whether improvement is due to physiological or psychological factors. Methods: Between 2002 and 2008, 8 patients had an array of questionnaires before and after SNM implantation. The questionnaires were: the Questionnaire for Screening for Sexual Dysfunctions, the Golombok Rust Inventory of Sexual Satisfaction, the Symptom Checklist-90, the Maudsley Marital Questionnaire and the McGill-Mah Orgasm Questionnaire. Three of these 8 patients underwent vaginal plethysmography before and after implantation. Results: No statistically significant changes were found, although there seems to be a trend toward improvement in orgasm scores. In plethysmography all 3 patients showed increased vaginal pulse amplitude with the stimulator turned on with both erotic and non-erotic stimuli. Conclusions: This study does not show a clear effect of SNM on sexual function, although there seems to be an improvement in orgasm scores. The lack of response on psychological questionnaires and the increase in vaginal pulse amplitude after SNM implantation indicate that there might be a physiological response.

Keywords:
Fecal incontinence, Females, Sexual function, Sacral neuromodulation, Urinary symptoms
1.
van Kerrebroeck PEV, et al: Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. J Urol 2007;178:2029–2034.
2.
Hassouna MM, et al: Sacral neuromodulation in the treatment of urgency-frequency symptoms: a multicenter study on efficacy and safety. J Urol 2000;163:1849–1854.
3.
Shaker HS, Hassouna M: Sacral nerve root neuromodulation: an effective treatment for refractory urge incontinence. J Urol 1998;159:1516–1519.
4.
Melenhorst J, et al: Sacral neuromodulation in patients with faecal incontinence: results of the first 100 permanent implantations. Colorectal Dis 2007;9:725–730.
5.
Kamm MA, et al: Sacral nerve stimulation for intractable constipation. Gut 2010;59:333–340.
6.
McKenna KE: The neurophysiology of female sexual function. World J Urol 2002;20:93–100.
7.
Shaker H: Role of C-afferent fibres in the mechanism of action in chronic spinal cord injury. BJU Int 2000;85:905–910.
8.
Das AK, Carlson AM, Hull M: Improvement in depression and health-related quality of life after sacral nerve stimulation therapy for treatment of voiding dysfunction. Urology 2004;64:62–68.
9.
Van Voskuilen AC, et al: Medium-term experience of sacral neuromodulation by tined lead implantation. BJU Int 2007;99:107–110.
10.
Spinelli M, et al: New sacral neuromodulation lead for percutaneous implantation using local anesthesia: description and first experience. J Urol 2003;170:1905–1907.
11.
Rust J, Golombok S: The Golombok-Rust Inventory of Sexual Satisfaction (GRISS). Br J Clin Psychol 1985;24(pt 1):63–64.
12.
ter Kuile MM, et al: The Golombok Rust Inventory of Sexual Satisfaction (GRISS): psychometric properties within a Dutch population. J Sex Marital Ther 1999;25:59–71.
13.
Derogatis LR, Lipman RS, Covi L: SCL-90: an outpatient psychiatric rating scale – preliminary report. Psychopharmacol Bull 1973;9:13–28.
14.
Arrindell WA, Schaap C: The Maudsley Marital Questionnaire (MMQ): an extension of its construct validity. Br J Psychiatry 1985;147:295–299.
15.
Orathinkal J, Vansteenwegen A, Stroobants R: Further validation of the Maudsley Marital Questionnaire (MMQ). Psychol Health Med 2007;12:346–352.
16.
Mah K, Binik YM: Are orgasms in the mind or the body? Psychosocial versus physiological correlates of orgasmic pleasure and satisfaction. J Sex Marital Ther 2005;31:187–200.
17.
Derogatis LR, Lipman RS, Covi L: SCL-90: an outpatient psychiatric rating scale – preliminary report. Psychopharmacol Bull 1973;9:13–28.
18.
Sintchak G, Geer JH: A vaginal plethysmograph system. Psychophysiology 1975;12:113–115.
19.
Laan E, Everaerd W, Evers A: Assessment of female sexual arousal: response specificity and construct validity. Psychophysiology 1995;32:476–485.
20.
Levin RJ, Macdonagh RP: Increased vaginal blood flow induced by implant electrical stimulation of sacral anterior roots in the conscious woman: a case study. Arch Sex Behav 1993;22:471–475.
21.
Geer JH, Janssen E: The sexual response system; in Cacioppo JT, Tassinary LG, Berntson GG (eds): Handbook of Psychophysiology, ed 2. Cambridge, Cambridge University Press, 2003, pp 315–340.
22.
Pauls RN, et al: Effects of sacral neuromodulation on female sexual function. Int Urogynecol J Pelvic Floor Dysfunct 2007;18:391–395.
23.
Lombardi G, et al: Clinical female sexual outcome after sacral neuromodulation implant for lower urinary tract symptom (LUTS). J Sex Med 2008;5:1411–1417.
24.
Zabihi N, et al: The effects of bilateral caudal epidural S2–4 neuromodulation on female sexual function. Int Urogynecol J Pelvic Floor Dysfunct 2008;19:697–700.
25.
Ingber MS, et al: Neuromodulation and female sexual function: does treatment for refractory voiding symptoms have an added benefit? Int Urogynecol J Pelvic Floor Dysfunct 2009;20:1055–1059.
26.
Spinelli M, et al: A new minimally invasive procedure for pudendal nerve stimulation to treat neurogenic bladder: description of the method and preliminary data. Neurourol Urodyn 2005;24:305–309.
27.
Jarrett ME, Nicholls RJ, Kamm MA: Effect of sacral neuromodulation for faecal incontinence on sexual activity. Colorectal Dis 2005;7:523–525.
28.
Chivers ML, et al: Agreement of self-reported and genital measures of sexual arousal in men and women: a meta-analysis. Arch Sex Behav 2010;39:5–56.
29.
Rellini AH, et al: The relationship between women’s subjective and physiological sexual arousal. Psychophysiology 2005;42:116–124.
30.
Meloy S: Neurally augmented sexual function. Acta Neurochir Suppl 2007;97(pt 1): 359–363.
31.
Govaert B, et al: The effect of sacral nerve stimulation on uterine activity: a pilot study. Colorectal Dis 2010;12:448–451.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.